Health: pharmaceuticals; prescription drug cost and affordability review act; create. Creates new act.
SB0003 creates the Michigan Prescription Drug Cost and Affordability Review Act. It establishes a new autonomous Prescription Drug Affordability Board within the Department of Insurance and Financial Services, along with a 21-member stakeholder council to advise it. The board is tasked with identifying certain high-cost or rapidly increasing prescription drug products, reviewing whether their prices create affordability problems for patients, hospitals, or health systems, and, if warranted, setting upper payment limits by rule.
The bill sets detailed criteria for review, including brand-name drugs and biologics with very high annual costs or large price increases, certain biosimilars that are not sufficiently discounted, and generic drugs that are expensive and have sharply increased in price. In conducting reviews, the board may examine manufacturer pricing decisions, rebates, therapeutic alternatives, patient cost-sharing, access programs, and hospital impacts. If the board finds affordability challenges, it may impose an upper payment limit, subject to limits such as no cap on drugs in FDA shortage and no inclusion of professional dispensing fees.
The bill also creates enforcement and administrative mechanisms. Purchasers and third-party payers would be prohibited from paying or reimbursing above an established upper payment limit, while certain providers such as independent pharmacies, hospitals, behavioral health hospitals, and 340B covered entities could not be reimbursed below that limit. The attorney general could investigate violations and seek civil relief, and aggrieved parties could appeal board decisions under the Administrative Procedures Act. The bill also creates a dedicated fund to support the board and implementation costs, requires annual reporting to the Legislature, and directs the board to conduct a one-time study on generic drug pricing, insurance costs, Medicaid spending, shortages, and 340B impacts.
The general sentiment reflected in the vote history suggests the bill was supported by a majority but remained controversial. It was reported favorably from committee 5-2 and then passed the Senate 20-15, indicating meaningful bipartisan or intra-party opposition rather than broad consensus. No committee transcript was provided, so the available record shows support for the bill’s affordability goals but also substantial concern about its regulatory approach.
The main points of contention appear to center on the board’s authority to set upper payment limits, the use of cost-effectiveness analysis, and the potential effects on manufacturers, pharmacies, hospitals, and 340B entities. The bill tries to address some of those concerns by barring the use of quality-adjusted life year measures to disadvantage people based on age or disability, excluding drugs in shortage, and protecting certain providers from being reimbursed below the cap. Even so, the structure gives a state board significant discretion over drug pricing, which is likely the core issue dividing supporters and opponents.
The bill would add a new chapter of state law governing prescription drug affordability review and price controls, centered in the Department of Insurance and Financial Services. It would create two new entities, a five-member Prescription Drug Affordability Board and a 21-member stakeholder council, and authorize the board to review selected prescription drug products and establish upper payment limits by rule. It would also create a new state fund, require annual legislative reporting and a one-time study, and authorize enforcement by the attorney general and appeals under the Administrative Procedures Act. The bill would directly affect manufacturers, health insurers, pharmacy benefit managers, self-funded plans, purchasers, pharmacies, hospitals, behavioral health hospitals, and 340B covered entities by limiting reimbursement and payment amounts for covered drugs.
The bill appears to have been viewed as a serious prescription-drug affordability measure with enough support to pass the Senate, but not without significant opposition. The 20-15 floor vote and 5-2 committee recommendation suggest a divided response, with supporters likely favoring stronger state action on drug prices and opponents concerned about government price-setting and market disruption. Because no committee transcript was provided, the record mainly shows that the bill advanced, but only after substantial debate and resistance.
The most notable contention is the board’s power to impose upper payment limits on drugs that it determines are causing affordability problems. Critics are likely to worry about state intervention in pricing, possible effects on innovation, and administrative burdens on manufacturers and payers, while supporters would emphasize relief for patients and health systems facing high drug costs. Additional friction points include the treatment of 340B covered entities, hospitals, pharmacies, and drug shortages, as well as the bill’s use of cost-effectiveness analysis and its restrictions on how such analysis may be used against older, sicker, or disabled patients. The bill also builds in conflict-of-interest restrictions on board membership, reflecting concern about industry influence over the new regulatory body.